OmniAb provides access to validated transgenic animal platforms, including the first heavy chain-only transgenic chicken, to generate high-quality, fully human antibodies for therapeutic discovery. This technology addresses the challenge of identifying diverse antibody repertoires for next-generation therapeutics in the pharmaceutical industry.
Funding
Funding not disclosed
Founders
Product
Problem
The pharmaceutical industry faces challenges in identifying diverse antibody repertoires for next-generation therapeutics. Traditional methods may not effectively generate high-quality, fully human antibodies needed for therapeutic discovery.
Solution
OmniAb provides access to validated transgenic animal platforms designed to generate fully human antibodies for therapeutic discovery. Their technology includes a heavy chain-only transgenic chicken, enabling greater immune recognition of highly conserved antigens and the discovery of more diverse antibody repertoires. By offering a comprehensive suite of clinically proven antibody discovery technologies, OmniAb enables partners to identify ideal therapeutic candidates. The platform aims to improve the efficiency and effectiveness of antibody discovery for next-generation therapeutics.
Target Audience
OmniAb's primary customers are pharmaceutical and biopharmaceutical companies and research institutions involved in clinical drug development.
Features
- Validated transgenic animal platforms for generating fully human antibodies.
- Heavy chain-only transgenic chicken for humanized single-domain antibody production.
- Enhanced immune recognition of highly conserved antigens.
- Access to diverse antibody repertoires.
- Cutting-edge screening technologies for antibody discovery.